Brokerages Set Pfizer Inc. (NYSE:PFE) PT at $36.33

Shares of Pfizer Inc. (NYSE:PFE) have earned an average rating of “Hold” from the sixteen analysts that are covering the firm, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $36.33.

Several equities research analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Finally, Guggenheim initiated coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Briaud Financial Planning Inc purchased a new position in shares of Pfizer during the 3rd quarter valued at about $30,000. GoalVest Advisory LLC lifted its holdings in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares in the last quarter. Creekmur Asset Management LLC purchased a new position in Pfizer in the 4th quarter worth approximately $32,000. Trivant Custom Portfolio Group LLC lifted its holdings in Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares in the last quarter. Finally, Mizuho Securities Co. Ltd. purchased a new position in Pfizer in the 3rd quarter worth approximately $34,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

NYSE PFE opened at $25.61 on Friday. Pfizer has a one year low of $25.20 and a one year high of $40.37. The stock has a 50-day moving average of $26.88 and a 200 day moving average of $28.26. The company has a market capitalization of $145.02 billion, a price-to-earnings ratio of 71.14, a PEG ratio of 1.14 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same period last year, the company earned $1.14 EPS. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. On average, sell-side analysts forecast that Pfizer will post 2.24 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.56%. Pfizer’s payout ratio is currently 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.